Biohaven Pharmaceutical Holding Cash on Hand 2016-2022 | BHVN

Biohaven Pharmaceutical Holding cash on hand from 2016 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
  • Biohaven Pharmaceutical Holding cash on hand for the quarter ending March 31, 2022 was $0.602B, a 6.4% increase year-over-year.
  • Biohaven Pharmaceutical Holding cash on hand for 2021 was $0.365B, a 2.61% increase from 2020.
  • Biohaven Pharmaceutical Holding cash on hand for 2020 was $0.355B, a 12.19% increase from 2019.
  • Biohaven Pharmaceutical Holding cash on hand for 2019 was $0.317B, a 19.86% increase from 2018.
Biohaven Pharmaceutical Holding Annual Cash on Hand
(Millions of US $)
2021 $365
2020 $355
2019 $317
2018 $264
2017 $131
2016 $24
2015 $1
Biohaven Pharmaceutical Holding Quarterly Cash on Hand
(Millions of US $)
2022-03-31 $602
2021-12-31 $365
2021-09-30 $520
2021-06-30 $366
2021-03-31 $566
2020-12-31 $355
2020-09-30 $546
2020-06-30 $261
2020-03-31 $428
2019-12-31
2019-09-30 $417
2019-06-30 $466
2019-03-31 $217
2018-12-31 $264
2018-09-30 $168
2018-06-30 $217
2018-03-31 $104
2017-12-31 $131
2017-09-30 $176
2017-06-30 $204
2017-03-31 $52
2016-12-31 $24
2016-09-30
2016-06-30
2016-03-31
2015-12-31 $1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.248B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00